Overall Survival
FIGURE 1 · Panel Overall_Survival
Panel Overall_Survival 是同一 FIGURE 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Jedd D Wolchok, Vanna Chiarion-Sileni, Piotr Rutkowski, C Lance Cowey, Dirk Schadendorf, John Wagstaff, Paola Queirolo, Reinhard Dummer, Marcus O Butler, Andrew G Hill, Michael A Postow, Caroline Gaudy-Marqueste, Theresa Medina, Christopher D Lao, John Walker, Iván Márquez-Rodas, John B A G Haanen, Massimo Guidoboni, Michele Maio, Patrick Schöffski, Matteo S Carlino, Shahneen Sandhu, Céleste Lebbé, Paolo A Ascierto, Georgina V Long, Corey Ritchings, Ayman Nassar, Margarita Askelson, Melanie Pe Benito, Wenjia Wang, F Stephen Hodi, James Larkin, CheckMate 067 Investigators
N Engl J Med 392(1) 11-22
BACKGROUND: Previous results from this trial showed longer overall survival after treatment with nivolumab plus ipilimumab or with nivolumab monotherapy than with ipilimumab monotherapy in patients with advanced melanoma. Given that patients with advanced melanoma are living longer than 7.5 years, longer-term data were needed to address new clinically relevant questions. METHODS: We randomly assigned patients with previously untreated advanced melanoma, in a 1:1:1 ratio, to one of the following regimens: nivolumab (1 mg per kilogram of body weight) plus ipilimumab (3 mg per kilogram) every 3 weeks for four doses, followed by nivolumab (3 mg per kilogram) every 2 weeks; nivolumab (3 mg per kilogram) every 2 weeks plus placebo; or ipilimumab (3 mg per kilogram) every 3 weeks for four doses plus placebo. Treatment was continued until the occurrence of disease progression, unacceptable toxic effects, or withdrawal of consent. Randomization was stratified according to BRAF mutation status, metastasis stage, and programmed death ligand 1 expression. Here, we report the final, 10-year results of this trial, including results for overall survival and melanoma-specific survival, as well as durability of response. RESULTS: With a minimum follow-up of 10 years, median overall survival was 71.9 months with nivolumab plus ipilimumab, 36.9 months with nivolumab, and 19.9 months with ipilimumab. The hazard ratio for death was 0.53 (95% confidence interval [CI], 0.44 to 0.65) for nivolumab plus ipilimumab as compared with ipilimumab and was 0.63 (95% CI, 0.52 to 0.76) for nivolumab as compared with ipilimumab. Median melanoma-specific survival was more than 120 months with nivolumab plus ipilimumab (not reached, with 37% of the patients alive at the end of the trial), 49.4 months with nivolumab, and 21.9 months with ipilimumab. Among patients who had been alive and progression-free at 3 years, 10-year melanoma-specific survival was 96% with nivolumab plus ipilimumab, 97% with nivolumab, and 88% with ipilimumab. CONCLUSIONS: The final trial results showed a continued, ongoing survival benefit with nivolumab plus ipilimumab and with nivolumab monotherapy, as compared with ipilimumab monotherapy, in patients with advanced melanoma. (Funded by Bristol Myers Squibb and others; CheckMate 067 ClinicalTrials.gov number, NCT01844505.).
2 个 Figure · 5 个 KM 面板
Overall Survival, Melanoma-Specific Survival and Progression-Free Survival in the Intention-to-Treat Population. Panel A shows overall survival among the intention-to-treat population. Panel B shows melanoma-specific survival among the intention-to-treat population. Melanoma-specific survival was a post-hoc analysis. Panel C shows progression-free survival among the intention-to-treat population. After 36-months, there were 38 total reported events for the progression-free survival analysis - 19 new progressions, 2 deaths due to melanoma without documented progression, and 17 deaths due to non-melanoma causes without progression; of those, 21 occurred after 60 months (8 new progressions, 2 deaths due to melanoma without documented progression, and 11 deaths due to non-melanoma causes without documented progression). Confidence interval widths have not been adjusted for multiplicity and should not be used in place of hypothesis testing. NIVO denotes nivolumab, IPI ipilimumab, and HR hazard ratio. *Descriptive comparison A. Overall Survival Among Intention-to-Treat Population B. Melanoma-Specific Survival Among Intention-to-Treat Population C. Progression-Free Survival Among Intention-to-Treat Population
FIGURE 1 · Panel Overall_Survival
Panel Overall_Survival 是同一 FIGURE 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Overall Survival and Melanoma-Specific Survival by BRAF Mutation Status Panels A and B show overall survival in the intention-to-treat population among patients with BRAF mutations and among patients without BRAF mutations, respectively. Panels C and D show melanoma-specific survival in the intention-to-treat population among patients with BRAF mutations and among patients without BRAF mutations, respectively. Melanoma-specific survival was a post-hoc analysis. Confidence interval widths have not been adjusted for multiplicity and should not be used in place of hypothesis testing. NIVO denotes nivolumab, IPI ipilimumab, HR hazard ratio, and NR not reached. *Descriptive comparison A. Overall Survival Among Intention-to-Treat Population with BRAF Mutations B. Overall Survival Among Intention-to-Treat Population without BRAF Mutations C. Melanoma-Specific Survival Among Intention-to-Treat Population with BRAF Mutations D. Melanoma-Specific Survival Among Intention-to-Treat Population without BRAF Mutations
FIGURE 2 · Panel A
Panel A 是同一 FIGURE 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIGURE 2 · Panel B
Panel B 是同一 FIGURE 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIGURE 2 · Panel C
Panel C 是同一 FIGURE 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIGURE 2 · Panel D
Panel D 是同一 FIGURE 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。